

Prof. MEHMET ALİ NAHİT ŞENDUR

Personal Information

Office Phone: [+90 312 552 600](tel:+90312552600)

Email: mansendur@aybu.edu.tr

Web: <https://avesis.aybu.edu.tr/mansendur>

International Researcher IDs

ORCID: 0000-0001-7021-6139

ScopusID: 57196215937

Yoksis Researcher ID: 169692

Education Information

Post Doctorate of Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, Ankara Numune Eğitim Ve Araştırma Hastanesi, Turkey 2011 - 2014

Expertise In Medicine, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, Turkey 2005 - 2010

Undergraduate, Hacettepe University, Tıp Fakültesi (İngilizce), Turkey 1998 - 2005

Research Areas

Health Sciences

Academic Titles / Tasks

Associate Professor, Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2015 - Continues

Advising Theses

ŞENDUR M. A. N., Investigation of the Effectiveness of Adjuvant Hormonal Treatment on Depression, Sleep Quality and Sexual Function in Hormone Receptor Positive Early Stage Breast Cancer, Expertise In Medicine, Y.KINACI(Student), 2020

ŞENDUR M. A. N., Investigation of Factors Affecting the Efficacy of Targeted Therapies in Patients with Metastatic Colorectal Cancer, Expertise In Medicine, Ş.TUTUM(Student), 2019

Published journal articles indexed by SCI, SSCI, and AHCI

- Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye**
Cicin I., Karadurmus N., BİLİCİ A., Bahsi T., ŞENDUR M. A. N., Demirci U., SEZGİN GÖKSU S., ER Ö., BİŞGİN A., Ozturk Saglam O. F., et al.
Future oncology (London, England), vol.20, no.15, pp.1031-1045, 2024 (SCI-Expanded)
- Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC**

Yildirim M. E., Karadurmuş N., Ökten İ. N., TÜRK H. M., Uraççı Z., Arslan Ç., Çelik S., Dane F., ŞENDUR M. A. N., Bilir C., et al.

Journal of Oncology Pharmacy Practice, 2024 (SCI-Expanded)

- III. **Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group**
Kaplan M. A., ŞENDUR M. A. N., Cangır A. K., Fırat P., Göker E., Kılıçkap S., OYAN ULUÇ B., Büge Öz A., ÖZDEMİR F., ÖZYİĞİT G.
Current Problems in Cancer, vol.47, no.6, 2023 (SCI-Expanded)
- IV. **Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskeletal events?**
Yağar H., Aytekin M. N., sener dede D., Sendur M., öztürk r., yalcin b.
Joint Diseases and Related Surgery, vol.35, no.1, pp.105-111, 2023 (SCI-Expanded)
- V. **Tamoxifen related chorioretinal structural changes**
Erbahçeci Timur İ. E., Açıkgöz V., Uğurlu N., Yalçın B., ŞENDUR M. A. N., Hızal M., KARA H.
Cutaneous and Ocular Toxicology, vol.42, no.3, pp.109-117, 2023 (SCI-Expanded)
- VI. **Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study**
Yekedüz E., ÖZBAY M. F., Çağlayan D., YILDIRIM A., Erol C., YILDIRIM H. Ç., Tunç S., Özyurt N., ÖZDEMİR F., ŞENDUR M. A. N., et al.
European Journal of Clinical Pharmacology, vol.78, no.12, pp.1973-1979, 2022 (SCI-Expanded)
- VII. **Adjuvant immunotherapy for renal cell carcinoma**
ŞENDUR M. A. N.
The Lancet. Oncology, vol.23, no.9, pp.1110-1111, 2022 (SCI-Expanded)
- VIII. **Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer**
Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., Şakalar T., EROL C., ŞENDUR M. A. N., ŞAHİN A. B., et al.
Tumori, vol.107, no.5, pp.416-423, 2021 (SCI-Expanded)
- IX. **The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement**
Bilgin B., ŞENDUR M. A. N., Yücel Ş., Hızal M., Güner G., Akyürek N., EROL C., AKINCI M. B., Dede D., YALÇIN B., et al.
Journal of Cancer Research and Clinical Oncology, vol.147, no.9, pp.2637-2643, 2021 (SCI-Expanded)
- X. **Can the host immune response against SARS-CoV2 also cause an anticancer effect?**
KAHRAMAN S., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B.
Medical Oncology, vol.38, no.8, 2021 (SCI-Expanded)
- XI. **“Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?**
Karacin C., Acar R., Bal O., Eren T., ŞENDUR M. A. N., Acikgoz Y., Karadurmus N., Imamoglu G. I., Oksuzoglu O. B., Dogan M.
Supportive Care in Cancer, vol.29, no.8, pp.4587-4593, 2021 (SCI-Expanded)
- XII. **Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study**
Bilgin B., ŞENDUR M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., Basoglu T., Ilhan A., Akdeniz N., Gulmez A., et al.
Journal of Cancer Research and Clinical Oncology, vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded)
- XIII. **A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint**
HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
Current Medical Research and Opinion, vol.36, no.4, pp.625-635, 2020 (SCI-Expanded)
- XIV. **Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?**
HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., Dede D., YALÇIN B.

Journal of B.U.ON., vol.24, no.4, pp.1367-1370, 2019 (SCI-Expanded)

- XV. **The current status of adjuvant treatment for high-risk renal cell carcinoma**
HIZAL M., ŞENDUR M. A. N., Bilgin B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
FUTURE ONCOLOGY, vol.13, no.23, pp.2017-2020, 2017 (SCI-Expanded)
- XVI. **Targeted therapies in gastric cancer and future perspectives**
Yazici O., ŞENDUR M. A. N., Ozdemir N., AKSOY S.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.22, no.2, pp.471-489, 2016 (SCI-Expanded)
- XVII. **A comprehensive review of denosumab for bone metastasis in patients with solid tumors**
Gul G., ŞENDUR M. A. N., AKSOY S., Sever A. R., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.32, no.1, pp.133-145, 2016 (SCI-Expanded)
- XVIII. **Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer**
ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N., Yazici O., Sever A. R., Altundag K.
JOURNAL OF BUON, vol.21, no.1, pp.27-34, 2016 (SCI-Expanded)
- XIX. **A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience**
Yazilitas D., Ozdemir N., Hocasade C., Bozkaya Y., Yazici O., ŞENDUR M. A. N., Zengin N.
JOURNAL OF BUON, vol.20, no.6, pp.1526-1533, 2015 (SCI-Expanded)
- XX. **Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature**
Ulas A., SILAY K., Akinci S., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., POLAT Y. H., YALÇIN B.
ONCOLOGY LETTERS, vol.10, no.4, pp.2223-2226, 2015 (SCI-Expanded)
- XXI. **Do Statins Really Improve Colorectal Cancer-Specific Mortality?**
ŞENDUR M. A. N., AKSOY S., Yalçin B.
JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.7, pp.811, 2015 (SCI-Expanded)
- XXII. **Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer**
ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., ŞENER DEDE D., Ulas A., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, no.8, pp.1141-1143, 2015 (SCI-Expanded)
- XXIII. **Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer**
ŞENDUR M. A. N., AKSOY S., AKINCI M. B., Ozdemir N., ŞENER DEDE D., Altundag K., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, no.6, pp.905-907, 2015 (SCI-Expanded)
- XXIV. **Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab**
ŞENDUR M. A. N., AKSOY S., Altundag K.
FUTURE ONCOLOGY, vol.11, no.1, pp.13-15, 2015 (SCI-Expanded)
- XXV. **Current Treatment Options for Metastatic Pancreatic Adenocarcinoma**
ŞENDUR M. A. N., Yazici O., Ozdemir N. Y., AKSOY S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, no.4, pp.263-274, 2015 (SCI-Expanded)
- XXVI. **Resistance to Androgen-Pathway Drugs in Prostate Cancer**
ŞENDUR M. A. N., AKINCI M. B., YALÇIN B.
NEW ENGLAND JOURNAL OF MEDICINE, vol.371, no.23, pp.2233, 2014 (SCI-Expanded)
- XXVII. **The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration**
ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., Zengin N., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.30, no.12, pp.2535-2542, 2014 (SCI-Expanded)
- XXVIII. **Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia**
Acikgoz Y., ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N.
MEDICAL ONCOLOGY, vol.31, no.9, 2014 (SCI-Expanded)
- XXIX. **Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients**

that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

ŞENDUR M. A. N., Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinçi A. S., Yazilitas D., Gunaydin Y., Oksuzoglu B., Benekli M., et al.

MEDICAL ONCOLOGY, vol.31, no.9, 2014 (SCI-Expanded)

XXX. Impact of Acetylsalicylic Acid on the Clinicopathological Characteristics and Prognosis of Patients with Invasive Breast Cancer

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N., Altundag K.

BREAST CARE, vol.9, no.4, pp.261-266, 2014 (SCI-Expanded)

XXXI. Lung Cancer Screening: A Comprehensive Review of the Literature with Detailed Data

Acikgoz Y., ŞENDUR M. A. N., Ozdemir N. Y., AKSOY S., Zengin N.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.4, pp.270-278, 2014 (SCI-Expanded)

XXXII. Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers

Cihan S., KÜÇÜKÖNER M., Ozdemir N., DANE F., ŞENDUR M. A. N., Yazilitas D., Urakci Z., Durnali A., Yuksel S., AKSOY S., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.13, pp.5337-5341, 2014 (SCI-Expanded)

XXXIII. Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., AKINCI M. B., Aksoy S., Zengin N.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded)

XXXIV. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients

Ozdemir N., AKSOY S., ŞENDUR M. A. N., AKINCI M. B., Yazici O., Budakoglu B., Abali H., Oksuzoglu B., ZENGİN N.

Journal of B.U.ON., vol.18, no.4, pp.831-837, 2013 (SCI-Expanded)

XXXV. Does zoledronic acid have additive effect on suppression of plasma estrogen levels?

ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., AKINCI M. B., ZENGİN N., Altundağ K.

Asian Pacific Journal of Cancer Prevention, vol.14, no.1, pp.607-608, 2013 (SCI-Expanded)

XXXVI. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?

ŞENDUR M. A. N., Özdemir N. Y., AKINCI M. B., Uncu D., ZENGİN N., AKSOY S.

World Journal of Gastroenterology, vol.19, no.1, pp.144-146, 2013 (SCI-Expanded)

XXXVII. New treatment trends in small cell carcinoma of the urinary bladder

ŞENDUR M. A. N., AKSOY S., Yazici O., AKINCI M. B., Ozdemir N., ZENGİN N.

Journal of B.U.ON., vol.17, no.4, pp.799-800, 2012 (SCI-Expanded)

Articles Published in Other Journals

I. Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials

Rauthan A., Jain A., Singh M., ŞENDUR M. A. N.

Oncology and Therapy, vol.12, no.3, pp.395-418, 2024 (ESCI)

II. Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer

Sekmek S., Ucar G., Karahan I., Bayram D., Aktürk Esen S., Seven I., ŞENDUR M. A. N., Uncu D.

African Journal of Urology, vol.29, no.1, 2023 (ESCI)

III. RETRACTED ARTICLE: Tarsconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors

Guler F., Yuksel N., KAHRAMAN S., ŞENDUR M. A. N.

Oncology and Therapy, vol.11, no.3, pp.391-396, 2023 (ESCI)

IV. Immunotherapy for Lung Cancer

Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., OYAN ULUÇ B., Yalman D.,

Yilmaz M. U., Yilmaz Ü., et al.

Journal of Oncological Science, vol.9, no.2, pp.97-111, 2023 (Scopus)

- V. **Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group**
Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., Şakalar T., EROL C., ŞENDUR M. A. N., ŞAHİN A. B., et al.
Journal of Gastrointestinal Cancer, vol.53, no.2, pp.282-288, 2022 (ESCI)
- VI. **The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer**
Hızal M., ŞENDUR M. A. N., Bilgin B., Karci Güner E., AKINCI M. B., Ergün Y., Esin E., KÖKSOY E. B., Sezer A., ÖZDEMİR N., et al.
Journal of Oncological Science, vol.8, no.2, pp.69-75, 2022 (Scopus)
- VII. **Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination**
Sümbül A. T., YALÇIN S. S., ÖZET A., ÜNAL S., DİZDAR Ö., Akbulut H., Karaoğlu A., Karadurmuş N., ŞENDUR M. A. N., Çilbir E., et al.
Journal of Oncological Science, vol.7, no.1, pp.1-6, 2021 (Scopus)
- VIII. **The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer Küçük hücreli dışı akciğer kanserinde yüksek pd-11 düzeyi ile ilişkili klinikopatolojik faktörlerin ve periferik kan parametrelerinin belirlenmesi**
Bilgin B., HIZAL M., Yücel Ş., ŞENDUR M. A. N., AKYÜREK N., AKINCI M. B., Yilmaz Ü., YALÇIN B.
Tuberkuloz ve Toraks, vol.68, no.2, pp.118-125, 2020 (ESCI)
- IX. **Prognostic importance of Albumin globulin ratio in small cell lung cancer Albümin Globulin Oraninin Küçük Hücreli Akciğer Kanserinde Prognostik Önemi**
BİLGİN B., ŞENDUR M. A. N., yücel Ş., HIZAL M., YALÇIN B.
Ankara Medical Journal, vol.18, no.4, pp.729-735, 2019 (Scopus)
- X. **Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients**
KARADURMUŞ N., ŞENDUR M. A. N., KARACA Ş. B., ÖLMEZ Ö. F., HACİBEKİROĞLU İ., COŞKUN H. Ş., DEĞİRMENCİOĞLU S., KEMAL Y., KILIÇKAP S., SÜMBÜL A. T., et al.
journal of oncological science, 2019 (Peer-Reviewed Journal)
- XI. **Evaluation of dynamic serum thiol-disulphide homeostasis in colorectal cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., kandil ulutaş s., yaman s., AKINCI M. B., ŞENER DEDE D., EREL Ö., YALÇIN B.
Journal of Oncological Sciences, 2019 (Peer-Reviewed Journal)
- XII. **Hyperthermia and radiotherapy combination for locoregional recurrences of breast cancer: a review**
Arslan S. A., Ozdemir N., ŞENDUR M. A. N., Eren T., Ozturk H. F., Aral I. P., Soykut E. D., Inan G. A.
BREAST CANCER MANAGEMENT, vol.6, no.4, pp.117-126, 2017 (ESCI)
- XIII. **Metastatic anal cloacogenic cell carcinoma misdiagnosed as urothelial carcinoma with long survival**
BİLGİN B., YALÇIN B., ŞENDUR M. A. N., AĞAÇKIRAN Y.
Journal of Oncological Sciences, vol.3, no.2, pp.87-88, 2017 (Peer-Reviewed Journal)
- XIV. **Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları Tek Merkez Deneyimi Demographic Characteristics and Treatment Outcomes of Patients with Renal Cell Cancer Single Center Experience**
ulaş a., BİLGİN B., ŞENER DEDE D., köş t., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B.
Ankara Medical Journal, 2016 (Peer-Reviewed Journal)
- XV. **Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey**
Ulas A., Silay K., Akinci S., Dede D., AKINCI M. B., ŞENDUR M. A. N., Cubukcu E., COŞKUN H. Ş., Degirmenci M., UTKAN G., et al.
Asian Pacific Journal of Cancer Prevention, vol.16, no.5, pp.1699-1705, 2015 (Scopus)

- XVI. **TÜRKİYE DE ONKOLOJİ HASTALARININ BİYOPSİKOSOSYAL VE KOZMİK İHTİYAÇLARI**
SILAY K., AKINCI M. B., ARİFE U., AKINCI S., ŞENDUR M. A. N., ŞENER DEDE D., YALÇIN B.
Türkiye Klinikleri Journal of Psychiatry Special Topics, vol.7, no.4, pp.1-4, 2014 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Gastrointestinal Kanal Subepitelyal Lezyonlarına Onkolojik Yaklaşım, Tedavi Endikasyonları**
BİLGİN B., ŞENDUR M. A. N.
in: Gastrointestinal Kanalin Subepitelyal Lezyonlari - 2020, Sabite Kaçar, Editor, Türkiye Klinikleri, pp.80-86, 2020
- II. **Baş Boyun Muayenesi. Anamnez ve Fizik Muayene Kitabı.**
ŞENDUR M. A. N.
in: Anamnez ve Fizik Muayene, Mehmet Ali Nahit Şendur, Muhammed Bülent Akıncı, Editor, Ankara Nobel Kitapevi, pp.33-52, 2019
- III. **Solunum sistemi muayenesi.**
ŞENER DEDE D., SILAY K., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B., DENİZ O., ÇAKIR B., AYHAN H., AYDIN C., ARGÜDER E., et al.
in: Erişkinlerde Anamnez ve Fizik Muayene, OSMAN ERSOY, ÖYKÜ TAYFUR YÜREKLİ, MEHMET ALİ NAHİT ŞENDUR, Editor, ANKARA NOBEL TIP KİTABEVİ, Ankara, pp.59-78, 2019
- IV. **Bazal Hücreli Kanserde Güncel Tedavi**
BİLGİN B., HIZAL M., ŞENDUR M. A. N.
in: Cilt Kanserleri, Umut Demirci, Editor, Türkiye Klinikleri, pp.72-76, 2019
- V. **İmmünoterapilerde Yan Etki Yönetimi**
ŞENDUR M. A. N.
in: İmmünoterapilerin Advers Etkileri ve Yönetimi, İrfan Çiçin, Editor, Türkiye Klinikleri, pp.8-17, 2019
- VI. **Bazal hücreli kanserde güncel tedavi**
BİLGİN B., HIZAL M., ŞENDUR M. A. N.
in: Cilt kanserleri, , Editor, Türkiye Klinikleri, pp.72-76, 2019
- VII. **Targeted Therapies and Immunotherapy in Bladder Cancer**
ŞENDUR M. A. N., AKSOY S.
in: Principles and Practice of UrooncologyRadiotherapy, Surgery and SystemicTherapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editor, Springer, pp.141-152, 2017

Refereed Congress / Symposium Publications in Proceedings

- I. **A case of hypophysitis with panhypopituitarism after the use of the immune check point inhibitor pembrolizumab**
Çopuroğlu E., FAKI S., BAŞER H., ŞENDUR M. A. N., Kılıç A., TOPALOĞLU O., ERSOY R., ÇAKIR B.
Endobridge 2021, 21 October 2021
- II. **EFFICACY AND SAFETY OF FOLFIRI/AFLIBERCEPT IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS (TOG STUDY)**
EROL C., HIZAL M., BİLGİTEKİN İ., akbaş s., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ÇİÇİN İ., ŞENDUR M. A. N., ARTAÇ M., et al.
10TH International Gastrointestinal Cancers Virtual Conference, Online, Turkey, 2 - 06 December 2020, pp.39-40
- III. **The incidence and prognostic significance of sarcopenia in advanced gastric cancer patients**
GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., ŞENDUR M. A. N.
10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 2 - 06 December 2020
- IV. **PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)** Cihan Ero11 , Mutlu Hızal2 , Irem Bilgetekin3 , Sinem Akbas4 , Duygu Bayir Garbioglu5 , Jamshid Hamdard6 , Cagatay Arslan7 , Alper Sevinc8 ,

Ahmet Kucukarda9 , Dilek Gurgenyatagi10, Emre Cakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, Izzet Dogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17, Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut Emre Yildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, Halil Taskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25, Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, Abdullah Sakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1 , Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, Semra Paydas35, Didem Tastekin14, Ilhan Hacibekiroglu11, Irfan Cicin9 , Ahmet Bilici6 , Didem Sener Dede1 , Muhammed Bulent Akinci1 , Nil Molinas Mandel36, Berna Oksuzoglu3 , Dogan Uncu2 , Bulent Yalcin1 , Mehmet Artac12, Mehmet Ali Nahit Sendur1

EROL C., HIZAL M., BİLGİN İ., akbaş s., ÇİÇİN İ., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ŞENDUR M. A. N. 10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

V. **The investigation of the related factors that affected targeted therapy outcome in metastatic colon cancer**

TUTUM Ş., BİLGİN B., HIZAL M., AKINCI M. B., YALÇIN B., ŞENDUR M. A. N.

10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 02 December 2020

VI. **THE INCIDENCE AND PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN ADVANCED GASTRIC CANCER PATIENTS**

GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., ŞENDUR M. A. N.

10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

VII. **Malign Glial Tümörlerin Klinikopatolojik Özellikleri ve Sağkalım Verilerinin İncelenmesi**

asan f. b., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., ASAN Ö., YALÇIN B., ŞENER DEDE D.

4. Uluslararası Hipokrat Tıp ve Sağlık Bilimleri Kongresi 25-26 Eylül 2020 Antalya, Türkiye, Antalya, Turkey, 25 September 2020, pp.925-932

VIII. **MALİGN GLİAL TÜMÖRLERİN KLİNİKOPATOLOJİK ÖZELLİKLERİ VE SAĞKALIM VERİLERİNİN İNCELENMESİ**

Aşan B., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., ASAN Ö., YALÇIN B., ŞENER DEDE D.

4th International Hippocrates Congress on Medical and Health Science, Turkey, 25 - 16 September 2020

IX. **Current Treatment Options in 2nd line Gastric Cancer and Ramucirumab**

KARADURMUŞ N., ŞENDUR M. A. N.

9th International Gastrointestinal Cancer Conference, 6 - 08 December 2019

X. **Give Her a long Life with Ribociclib in HR HER- aBC**

ŞENDUR M. A. N.

6th congress of the mediterranean multidisciplinary oncology forum, 28 November - 01 December 2019

XI. **EFFICACY AND SUCCESS OF AF ABLATION IN CANCER PATIENTS**

ATEŞ A. H., ŞENER Y. Z., ŞENDUR M. A. N., KILIÇKAP S., AYTEMİR K.

3.ULUSAL İMMİNÖTERAPİ VE ONKOLOJİ KONGRESİ, Turkey, 30 October - 03 November 2019

XII. **Timing of ADT in the Era of Stampede and Latitude**

ŞENDUR M. A. N.

World Urological Oncology Federation Symposium, 17 October 2019

XIII. **GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİ METASTATİK PROSTAT KANSERİ**

(KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

ALKAN A., SEVGİN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.300

XIV. **Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Doksetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi**

ALKAN A., SEVGİN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.185

XV. **GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİ METASTATİK PROSTAT KANSERİ (KDMPK)**

HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUÇLARI- GERÇEK YAŞAM VERİSİ

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.

23. ULUSAL KANSER KONGRESİ - 2019, Turkey, 17 - 21 April 2019

- XVI. **Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥ 75 Yaş) Hastalarda 1. Basamak Dositaksel Tedavi Sonuçları- Gerçek Yaşam Verisi**
ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., AKIN TELLİ T., KESKİN Ö., ARSLAN Ç., BİLGİN B., et al.
23. Ulusal Kanser Kongresi - 2019, Turkey, 17 - 21 April 2019
- XVII. **Increasing role of genetics in the management of pancreatic cancer**
ŞENDUR M. A. N.
8th International Gastrointestinal Cancers Conference, 7 - 09 December 2018
- XVIII. **COMBINATION OF OxALIPLATIN, CAPECITABINE, r a s t u z u m a b a n d c h e m o r a d i o t h e r a p y INPATIENTS WITH GASTRIC CANCER**
ABALI H., YALÇIN Ş., ÖNAL H. C., DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., MERTSOYLU H., ARTAÇ M., camcı c., başol f., et al.
8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018
- XIX. **Crizotinib efficacy in ALK-positive advanced stage non-small cell lung cancer patients: a real-world experience from Turkey.**
KILIÇKAP S., Öztürk A., KARADURMUŞ N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., PAYDAŞ S., ÇILBİR E., Sakalar T., UYSAL M., et al.
IASLC 19th World Conference On Lung Cancer, Canada, 23 - 26 September 2018, vol.13, pp.1020
- XX. **Neoadjuvant Treatment of Bladder Cancer**
ŞENDUR M. A. N.
8th Eurasian Uro-oncology Congress, 28 June - 01 July 2018
- XXI. **Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey**
Zengin G., Özyurt N., BEYPINAR İ., Çınkır H. Y., Bilgin B., GÜMÜŞAY Ö., ERTÜRK İ., ŞENDUR M. A. N., UYSAL M., ÜRÜN Y., et al.
ASCO 2018, 1 - 05 June 2018, vol.36, pp.15551
- XXII. **Case report: management of a patient with malignant insulinoma**
TOPALOĞLU O., ŞENDUR M. A. N., DUMLU E. G., YILDIRIM F., TAŞKALDIRAN I., SOYDAL Ç., ERSOY R., ÇAKIR B.
20th European Congress of Endocrinology, 19 - 22 May 2018
- XXIII. **Detection of pulmonary metastases with 18F-Fluorocholine PET/CT and treatment of refractory hypercalcemia with denosumab in a patient with long term parathyroid carcinoma**
TOPALOĞLU O., ŞENDUR M. A. N., DUMLU E. G., YILDIRIM F., TAŞKALDIRAN I., SOYDAL Ç., ERSOY R., ÇAKIR B.
20th European Congress of Endocrinology, 19 - 22 May 2018
- XXIV. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**
ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., KÖKSOY E. B., DEMİRCİ N. S., ŞENDUR M. A. N., DEDE İ., SEZER A., KARCI E., ÖZDEMİR N., YALÇIN B., et al.
JOURNAL OF CLINICAL ONCOLOGY, 1 - 05 June 2018, vol.36
- XXV. **Metastatik Pankreas Kanseri 2. Basamak Tedavilerin Etkinliği**
ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN B., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXVI. **Metastatik Pankreas Kanseri İkinci Basamak Tedavi Öncesi Prognostik Belirteçlerin Saptanması**
BİLGİN B., ŞENDUR M. A. N., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN B., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXVII. **The Role of Dynamic Serum Thiol-Disulphide Homeostasis in Metastatic Gastric Cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., DEDE D. Ş., YAMAN S., NEŞELİOĞLU S., ÖZDEMİR N., EREL Ö.,

- YALÇIN B.
7TH INTERNATIONAL GASTROINTESTINAL CANCERS CONFERENCE, İstanbul, Turkey, 15 - 17 December 2017
- XXVIII. **Assesment of nutritional status in cancer patients**
ŞENDUR M. A. N.
7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017
- XXIX. **Evaluation of dynamic serum thiol disulphide homeostasis in colorectal cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., ŞENER DEDE D., Yaman S., NEŞELİOĞLU S., ÖZDEMİR N., EREL Ö., YALÇIN B.
7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017
- XXX. **Young oncologists asking experts answering**
ŞENDUR M. A. N.
7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017
- XXXI. **The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)**
ŞENER DEDE D., TATLI DOĞAN H., ASAN F. B., GÜMÜŞKAYA ÖCAL B., AYIK Ş., ŞENDUR M. A. N., ULAŞ A., BİLGİN B., AKINCI M. B., SILAY K., et al.
42nd ESMO Congress (ESMO 2017), 8 - 12 September 2017
- XXXII. **Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction**
ÖZDEMİR N., Toptaş Ş., ŞENDUR M. A. N., Yazıcı O., ÇAKMAK ÖKSÜZOĞLU Ö. B., SILAY K., ZENGİN N.
42nd ESMO Congress (ESMO 2017), 8 - 12 September 2017
- XXXIII. **MEtaStatik vE nEoadjuvant tEdavi alan tRanSizyonEl HÜcREli MESanE kanSERindE HuMan EquiliBRativE nuclEoSidE tRanSpORtER 1 (HEnt1) MolEkÜlÜnÜn pREDiktiF vE pRognoStik önEMinin dEğERiEndiRilMESi**
ŞENER DEDE D., KILIÇARSLAN A., ULAŞ A., ŞENDUR M. A. N., YAMAN S., BİLGİN B., HIZAL M., AKINCI M. B., SILAY K., DEMİRCİ U., et al.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXIV. **2016 yIlInda tÜRkiyE kaynaklı onkolojik yayInlaR**
ŞENDUR M. A. N., BİLGİN B., HIZAL M., ÖZDEMİR N., AKINCI M. B., ŞENER DEDE D., YAZICI O., SILAY K., ZENGİN N., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXV. **İLERi EvRE koloREktal kanSERiERdE RdW-platElEt oRanInIn pRognoStik önEMi**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ŞENER DEDE D., YALÇIN A., SILAY K., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXVI. **t790M MutaSyonu pozitiF akciğER kanSERindE oSiMERTiniB diREnci; olgu SunuMu**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., ŞENER DEDE D., AKINCI M. B., SILAY K., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXVII. **özEFaguS yaSSi HÜcREli kaRSinoMlaRda lokal tEdavi StRatEjilERi vE pRognoStik FaktÖRiER**
ÖZDEMİR N., DİKİCİ H. Z., ARSLAN S., YAZICI O., ŞENDUR M. A. N., SILAY K., ZENGİN N.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXVIII. **FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER**
ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B., ŞENDUR M. A. N., BİLGİN B., Bozkurt U. B., demir m., et al.
International Congress on Oncological Sciences, 27 September - 01 October 2017
- XXXIX. **Prognostic importance red cell disturbance width to platelet ratio in advanced colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ S. K., ÖZDEMİR N., ŞENER DEDE D., YALÇIN A., YALÇIN B.
6th international Gastrointestinal cancer conferance December 2016 Antalya, Turkey, 2 November - 06 December 2016
- XL. **EFFECT OF RED CELL DISTURBATION WIDTH TO PLATELET RATIO ON DISEASE FREE SURVIVAL IN**

EARLY STAGE COLORECTAL CANCER

BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., Özdemir N. Y., Yaman S., Kandil S. U., YALÇIN A., KILIÇ M., et al.

6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016

- XLII. THE NEUTROPHIL LYMPHOCYTE RATIO MAY HAVE PROGNOSTIC EFFECT IN THE METASTATIC COLORECTAL CANCER**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., Dede D. Ş., AKINCI M. B., Kandil S. U., Yaman S., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XLIII. Local treatment strategies for esophageal SCC and prognostic factors**
ÖZDEMİR N., Dikici H. Z., Arslan S. A., Yazıcı O., ŞENDUR M. A. N., Bal Ö., ZENGİN N.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLIV. Prognostic significance of residual tumor size after chemoradiotherapy for rectal adenocarcinoma**
ÖZDEMİR N., Bozkaya Y., Aytaç Arslan S., Yazıcı O., ŞENDUR M. A. N., ZENGİN N.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLV. PROGNOSTIC IMPORTANCE RED CELL DISTURBATION WIDTH TO PLATELET RATIO IN ADVANCED COLORECTAL CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., Yaman S., Kandil S. U., Özdemir N. Y., ŞENER DEDE D., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XLVI. EFFECT OF THE RAS STATUS ON SURVIVAL IN ADVANCED COLON CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., Kandil S. U., Yaman S., AKINCI M. B., Dede D. Ş., Özdemir N. Y., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XLVII. THE PROGNOSTIC FACTORS IN STAGE 3 COLORECTAL CANCER PATIENTS**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., Yaman S., Kandil S. U., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XLVIII. Rituximab for primary extranodal lymphomas effectiveness**
ÖZDEMİR N., Aytaç Arslan S., Hocaşade C., Bozkaya Y., Yazıcı O., ŞENDUR M. A. N., ZENGİN N.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLIX. METASTATIC COLORECTAL CANCER SURVIVAL IS THERE A DIFFERENCE BETWEEN SYNCHRONOUS OR METACHRONOUS TUMORS**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., Dede D. Ş., AKINCI M. B., Yaman S., Kandil S. U., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- L. Tumor size in early stage N0 gastric carcinoma is it prognostic**
ÖZDEMİR N., KOCABAŞ M., ARSLAN S., Yazıcı O., ŞENDUR M. A. N., Algin E., ZENGİN N.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- L. ASSOCIATION BETWEEN TUMOR LOCALISATION AND CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OF COLORECTAL CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., Yaman S., Ulutaş Kandil S., ÖZDEMİR N., KILIÇ M., YALÇIN B.
6th International gastrointestinal cancer conference, 2 - 04 December 2016
- LI. Association between tumor localisation and clinicopathological characteristics and survival of colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., Yaman S., Ulutaş Kandil S., ÖZDEMİR N., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LII. Local treatment strategies for esophageal scc and prognostic factors**
ÖZDEMİR N., Dikici H., AYTAÇ ARSLAN S., yazıcı o., ŞENDUR M. A. N., bal ö., ZENGİN N.
6th international gis conference, 02 December 2016

- LIII. **Gastric cancer with lung metastasis and concurrent miliary tuberculosis**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LIV. **A rare case metastatic anal cloacogenic transitional cell carcinoma**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ŞENER DEDE D., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LV. **Compare tumor features and survival in right sided and left sided early stage colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., ÖZDEMİR N., YAMAN S., ULUTAŞ KANDİL S., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LVI. **ASSESSMENT OF THE COST EFFECTIVENESS OF THE FIRST LINE TARGETED THERAPIES FOR ADVANCED COLON CANCER IN TURKEY**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., ULUTAŞ KANDİL S., YAMAN S., AKINCI M. B., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- LVII. **Prognostic significance of residual tumor size after chemoradiotherapy for rectal adenocarcinoma**
ÖZDEMİR N., BOZKAYA Y., AYTAÇ ARSLAN S., YAZICI O., ŞENDUR M. A. N.
6th International GIS Conference, 2 - 04 December 2016
- LVIII. **Effects of neutrophil lymphocyte ratio and platelet lymphocyte ratio on survival of non metastatic colorectal cancer**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., ULUTAŞ KANDİL S., YAMAN S., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LIX. **Metastatic colorectal cancer survival Is there a difference between synchronous or metachronous tumors**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- LX. **Effect of using different antihypertensive drugs on demographic and clinico pathological characteristics of breast cancer**
M A Sendur¹ S Aksoy² N Ozdemir¹ O Yazici³ M B Akinci¹ D S Dede¹ B Yalçin¹ N Zengin¹ K Altundag²
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., YAZICI O., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
ESMO, 7 - 11 November 2016
- LXI. **Association between tumor localisation and Clinicopathologic characteristics and survival of colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ÖZDEMİR N., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancer Conference December 2016 Antalya, Turkey, 2 - 06 November 2016
- LXII. **Effect of red cell disturbance width to platelet ratio on disease free survival in early stage colorectal cancer**
BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., ÖZDEMİR N., YAMAN S., ULUTAŞ KANDİL S., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference December 2016 Antalya, Turkey, 2 - 06 November 2016
- LXIII. **Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer**
YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.
41st ESMO Congress (ESMO 2016), 7 - 11 October 2016
- LXIV. **Prognostic role of tumor location in stage 3 colorectal cancer patients received adjuvant chemotherapy**
ÖZDEMİR N., AYTAÇ ARSLAN S., ERDOĞAN K., YAZICI O., ŞENDUR M. A. N., BOZKAYA Y., ZENGİN N.
ESMO 2016, 7 - 11 October 2016
- LXV. **Efficacy of statin usage before diagnosis on clinico pathological characteristics and outcome of**

invasive breast cancer Annals of Oncology

ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., yazıcı o., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
41st ESMO Congress (ESMO 2016), 7 - 11 October 2016

- LXVI. **Comparison of clinical outcomes in patents with early stage ER PR HER2 breast cancer patients with triple negatives**
YAZICI O., ERDEM G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., DOĞAN M., ZENGİN N., ALTUNDAĞ K.
2016 ASCO Annual Meeting, 3 - 07 June 2016
- LXVII. **Adjuvant chemotherapy for esophageal scc**
ÖZDEMİR N., AYTAÇ ARSLAN S., ŞENDUR M. A. N.
6th international gis conference, 2 - 04 December 2016
- LXVIII. **METASTATİK MALİGN MELANOMDA BİRİNCİ BASAMAK TEDAVİLERİN MALİYET ANALİZİ**
BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., ULAŞ A., YAMAN S., BAŞER S., YALÇIN B.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016
- LXIX. **METASTATİK KOLON KANSERİ HASTALARINDA BİRİNCİ BASAMAK HEDEFE YÖNELİK TEDAVİLERİN MALİYET ANALİZİ**
BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ULAŞ A., YAMAN S., BAŞER S., YALÇIN B.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016
- LXX. **A novel strategy for determining circulating tumour cells in lung cancer**
ARKAN T. K., ÖZ B. E., ERSAN B., ERCAN E., ŞENDUR M. A. N., ALPARSLAN PINARLI F., ŞİMŞEK E., ÇARHAN A., ÖZENSOY GÜLER Ö.
10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, Germany, 19 - 21 March 2016
- LXXI. **A novel strategy for determining circulating tumour cells in lungcancer**
Arkan T. K., ÖZ B. E., Ersan B., Ercan E., ŞENDUR M. A. N., Alparslan Pınarlı F., ŞİMŞEK E., ÇARHAN A., ÖZENSOY GÜLER Ö.
10th ISMRC International Symposium on Minimal Residual Cancer Liquid Biopsy in Cancer Diagnostic and Treatment, Hamburg, Germany, 19 - 21 March 2016, pp.73
- LXXII. **A novel strategy for determining circulating tumour cells in lung cancer**
ARKAN T. K., ÖZ B. E., Bilgesu E., ERCAN E., ŞENDUR M. A. N., Alparslan Pınarlı F., ŞİMŞEK E., ÇARHAN A., ÖZENSOY GÜLER Ö.
10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, 19 - 21 March 2016
- LXXIII. **The effect of body mass index in patients with relapsed colorectal cancer**
Yazıcı O., Yazılıtaş D., ÖZDEMİR N., Demirci N. S., Erdem G., Bozkaya Y., Hocaşade C., Uçar g., Bal Ö., Doğan M., et al.
5th International Gastrointestinal Cancers Conference, 4-6 December 2015, İstanbul-Turkey, 4 - 06 December 2015
- LXXIV. **Multiple Akciğer ve Kemik Metastazı Yapan Deri Eki Tümörü**
KIRAN M. M., TATLI DOĞAN H., SÜNGÜ N., ŞENDUR M. A. N.
25.Ulusal Patoloji Kongresi, Turkey, 14 - 17 October 2015
- LXXV. **STUDY OF THE IMPACT OF CHARLSON COMORBIDITY INDEX ON THE EFFICACY OF ADJUVANT TRASTUZUMAB IN PATIENTS WITH HER 2 POSITIVE EARLY BREAST CANCER**
ŞENDUR M. A. N., AKSOY S., SILAY K., ÖZDEMİR N., OZAN Y., AKINCI M. B., ŞENER DEDE D., ZENGİN N., ZENGİN N., ALTUNDAĞ M. K.
18TH ECCO-40TH ESMO 2015, 25 - 29 September 2015
- LXXVI. **THE EFFECT OF INTERNATIONAL PROGNOSTIC INDEX IPI IN THE DETERMINATION OF PROGNOSIS OF EARLY STAGE DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA IS IT ENOUGH**
ÖZDEMİR N., YAZICI O., HOCAŞADE C., BOZKAYA Y., ŞENDUR M. A. N., AKINCI M. B., SILAY K., YAZILITAŞ D., TOPBAŞ Ş., ZENGİN N.
18TH ECCO-40TH ESMO 2015, 25 - 29 September 2015
- LXXVII. **Study of the impact of Charlson comorbidity index on the efficacy of adjuvant trastuzumab in patients with HER2 positive early breast cancer**

- ŞENDUR M. A. N., AKSOY S., SILAY K., ÖZDEMİR N., YAZICI O., AKINCI M. B., ZENGİN N., ALTUNDAĞ M. K.
18th ECCO-40th ESMO European Cancer Congress 25-29 September 2015, Vienna, Austria, European Journal of Cancer, Volume 51, Supplement 3, September 2015, S322, 25 - 29 September 2015
- LXXVIII. **The importance of thiol disulphide homeostasis in patients with advanced gastric cancer AGC receiving modified docetaxel and cisplatin plus fluorouracil mDCF regimen**
Yazıcı O., ÖZDEMİR N., EREL Ö., Demirci N. S., AKSOY S., ŞENDUR M. A. N., Doğan M., Yazılıtaş D., Erdem G. U., NEŞELİOĞLU S., et al.
18th ECCO-40th ESMO European Cancer Congress 25-29 September 2015, Vienna, Austria, European Journal of Cancer, Volume 51, Supplement 3, September 2015, S468., 25 - 29 September 2015
- LXXIX. **The efficacy and predictive factors of response of second line triplet modified EOX epirubicin oxaliplatin capecitabine regimen in metastatic gastric cancer**
ŞENDUR M. A. N., ÖZDEMİR N., AKSOY S., yazıcı o., yazılıtaş d., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N.
ESMO European Cancer Congress, 25 - 29 September 2015
- LXXX. **Tumor locations significantly affect disease free survival and overall survival**
BÜYÜKHATİPOĞLU H., Babacan T., KERTMEN N., Ateş Ö., Aktaş G., ŞENDUR M. A. N., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr e12590), 30 May - 03 June 2015
- LXXXI. **STUDY OF THE IMPACT OF CHARLSON COMORBIDITY INDEX ON THE EFFICACY OF AROMATASE INHIBITORS IN PATIENTS WITH HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL BREAST CANCER**
ŞENDUR M. A. N., AKSOY S., SILAY K., AKINCI M. B., ÖZDEMİR N., OZAN Y., ÖZBEK S., ZENGİN N., ALTUNDAĞ M. K.
ASCO (AMERICAN SOCIETY OF CLINICAL ONCOLOGY) 2015, 29 May - 06 June 2015
- LXXXII. **Does age play a role in peripheral neuropathy in multiple myeloma patients**
SILAY K., AKINCI S., ULAŞ A., GÜNEY T., AKINCI M. B., YALÇIN A., ŞENDUR M. A. N., DİLEK İ.
5th international congress on leukemia lymphomamyeloma, 21 - 23 May 2015
- LXXXIII. **MULTIPLE MYELOMA HASTALARINDA GÖRÜLEN PERİFERİK NÖROPATİDE YAŞIN ROLÜ**
SILAY K., AKINCI S., ULAŞ A., GÜNEY T., AKINCI M. B., YALÇIN A., ŞENDUR M. A. N., DİLEK İ.
8. AKADEMİK GERİATRİ KONGRESİ 2015, Turkey, 19 April 2015
- LXXXIV. **DIAGNOSIS TREATMENT CHARACTERISTICS AND COMORBIDITY OF WOMEN OF BREAST CANCER AGED 65 AND OLDER VERSUS 80 AND OLDER**
SILAY K., ÖZDEMİR N., ŞENDUR M. A. N., AKSOY S., ALTUNDAĞ M. K.
THE AMERICAN GERIATRIC SOCIETY 2014 ANNUAL SCIENTIFIC MEETING, 15 May 2014
- LXXXV. **Efficacy of adjuvant tamoxifen in hormone receptor positive premenopausal breast cancer patients according to the body mass index**
ALTUNDAĞ M. K., ŞENDUR M. A. N., AKSOY S., BABACAN T., ÖZİŞİK Y. Y.
2014 San Antonio Breast Cancer Symposium, 9 - 13 December 2014

Supported Projects

ŞENDUR M. A. N., Project Supported by Higher Education Institutions, MAKALE DESTEK, 2016 - 2017

Metrics

Publication: 145

Citation (WoS): 60

Citation (Scopus): 141

H-Index (WoS): 4

H-Index (Scopus): 4

Non Academic Experience

ANKARA NUMUNE EĐİTİM VE ARAŐTIRMA HASTANESİ
NİĐDE DEVLET HASTANESİ